Want to join the conversation?
$AGN will also pay Akarna potential clinical, regulatory and commercial milestone payments related to AKN-083, its lead development compound. AKN-083 is in development for treating Non-Alcoholic Steatohepatitis, a severe type of non-alcoholic fatty liver disease.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.